```html

Methotrexate Toxicity: A Complete Patient Guide

Overview

Methotrexate toxicity occurs when the drug methotrexate (MTX) builds up to harmful levels in the body, damaging organs such as the bone marrow, liver, kidneys, lungs, and gastrointestinal (GI) tract. Methotrexate is a folate antagonist used at low doses for autoimmune diseases (e.g., rheumatoid arthritis, psoriasis) and at high doses for certain cancers.

While it is a cornerstone therapy for many chronic conditions, toxicity can be life‑threatening if not recognized early. An estimated CDC reports that approximately 2–5 % of patients on low‑dose methotrexate develop clinically significant toxicity each year, with higher rates in oncology settings where dosages are much larger.

Anyone taking methotrexate—children, adults, pregnant or non‑pregnant individuals—can be affected, but the risk is higher among:

• Patients with renal impairment
• Elderly patients (≥ 65 years)
• Those taking interacting medications (e.g., NSAIDs, proton‑pump inhibitors, trimethoprim‑sulfamethoxazole)
• Patients with poor nutritional status or folate deficiency

Symptoms

Symptoms vary by organ system and can develop over hours to weeks after a dosing error, missed dose, or drug interaction. A comprehensive list includes:

Hematologic

• Aplastic anemia – fatigue, easy bruising, bleeding, pale skin.
• Leukopenia – recurrent infections, fever, sore throat.
• Thrombocytopenia – petechiae, prolonged bleeding from cuts.

Gastrointestinal

• Nausea & vomiting (often severe, may be hemorrhagic)
• Oral ulcerations or mucositis
• Abdominal pain, diarrhea, or constipation
• Hepatic tenderness

Dermatologic

• Photosensitivity and rash
• Severe cutaneous ulcerations, especially on pressure points
• Hair loss (alopecia)

Renal

• Acute kidney injury – reduced urine output, swelling, flank pain.

Hepatic

• Elevated liver enzymes (AST, ALT, ALP)
• Jaundice, right‑upper‑quadrant discomfort
• Progressive fibrosis or cirrhosis with chronic toxicity.

Pulmonary

• Dry cough, dyspnea, fever – methotrexate‑induced pneumonitis.
• Chest pain or pleuritic discomfort.

Neurologic & Other

• Headache, dizziness, confusion, seizures (rare, seen with high‑dose MTX).
• Peripheral neuropathy (tingling, numbness).
• Fever of unknown origin.

Causes and Risk Factors

Understanding why toxicity occurs helps prevent it.

Primary Causes

• Overdose – accidental (e.g., prescribing error) or intentional.
• Impaired drug clearance – especially reduced glomerular filtration.
• Drug interactions – agents that displace MTX from plasma proteins or reduce renal excretion.
• Missed folic acid supplementation – folic acid mitigates MTX’s effect on normal cells.

Risk Factors

• Renal dysfunction (eGFR < 60 mL/min/1.73 m²)
• Concomitant nephrotoxic drugs (e.g., aminoglycosides, NSAIDs, contrast agents)
• Low albumin levels (< 3.5 g/dL)
• Advanced age
• Pre‑existing liver disease or hepatitis
• Obesity (higher MTX volume of distribution)
• Genetic polymorphisms affecting MTX metabolism (e.g., MTHFR variants)
• Poor adherence to dosing schedule or folic acid supplementation

Diagnosis

Diagnosing methanol toxicity relies on a combination of clinical suspicion, laboratory testing, and imaging when needed.

History & Physical Examination

• Recent methotrexate dose, route (oral, subcutaneous, intramuscular), and timing.
• Review of concomitant medications and recent kidney‑affecting events (e.g., dehydration).
• Physical signs: oral ulcers, hepatomegaly, rash, respiratory findings.

Laboratory Tests

• Complete blood count (CBC) – looks for pancytopenia.
• Liver function tests (AST, ALT, ALP, bilirubin) – assess hepatotoxicity.
• Serum creatinine & BUN – gauge renal clearance.
• Serum methotrexate level – measured 24 h after high‑dose MTX; > 0.1 µM at 24 h suggests delayed clearance.
• Electrolytes – monitor for metabolic acidosis.
• Folate level (optional) – low levels support diagnosis.

Imaging & Specialized Tests

• Chest X‑ray or CT if pulmonary symptoms present (to detect pneumonitis).
• Abdominal ultrasound or FibroScan for chronic liver injury.
• Bone marrow biopsy only if severe cytopenias of unknown cause.

Diagnostic Criteria (Practical)

Clinically suspected toxicity is confirmed when any of the following are present:

1. Elevated serum MTX level beyond expected clearance AND/OR
2. New‑onset organ dysfunction (hematologic, hepatic, renal, pulmonary) temporally related to MTX administration AND
3. Absence of an alternative explanation.

Treatment Options

Management is time‑sensitive and usually occurs in a hospital setting.

Immediate Measures

• Stop methotrexate immediately.
• Hydration with intravenous (IV) normal saline (≥ 2 L/24 h) to enhance renal clearance.
• Correct electrolyte abnormalities (especially bicarbonate for metabolic acidosis).

Specific Antidotes

• Leucovorin (folinic acid) rescue – 15 mg IV/PO every 6 h, started as soon as possible; dosing depends on MTX level and renal function (e.g., 50 mg every 6 h for high‑dose MTX). Continue until MTX level < 0.05 µM.
• Glucarpidase (carboxypeptidase‑G2) – enzymatic degradation of MTX. Indicated when MTX > 1 µM after 48 h or when renal failure prevents clearance. Dose: 50 U/kg IV over 5 min; repeat after 24 h if needed.

Supportive Care

• Transfusion of packed red cells or platelets for severe cytopenias.
• Broad‑spectrum antibiotics if neutropenia with fever.
• Hepatoprotective measures – N‑acetylcysteine (controversial) or cessation of alcohol.
• Bronchodilators and steroids (e.g., prednisolone 1 mg/kg) for confirmed methotrexate‑induced pneumonitis.
• Renal replacement therapy (hemodialysis) is rarely effective for MTX itself but can manage severe AKI or fluid overload.

Long‑Term Management

• Re‑evaluate the need for methotrexate; consider alternative disease‑modifying agents (e.g., biologics for rheumatoid arthritis).
• If re‑challenge is required, reduce dose by 25–50 % and monitor levels closely.
• Implement lifelong folic acid supplementation (1–5 mg daily) unless contraindicated.

Living with Methotrexate Toxicity

Even after an acute episode, patients may need ongoing adjustments.

Medication Management

• Keep an updated medication list; share it with every health‑care provider.
• Never miss scheduled folic or folinic acid doses.
• Use a pill organizer or smartphone reminder.

Monitoring

• Laboratory checks: CBC, LFTs, creatinine every 2–4 weeks for the first 3 months, then every 3 months if stable (per Mayo Clinic guidelines).
• Report any new oral ulcers, unexplained bruising, shortness of breath, or jaundice immediately.

Lifestyle Adjustments

• Stay well‑hydrated (≥ 2 L water daily) unless fluid‑restricted.
• Avoid NSAIDs, aspirin, and other nephrotoxic agents unless prescribed.
• Limit alcohol consumption (< 2 drinks/week) to protect the liver.
• Maintain a balanced diet rich in leafy greens, legumes, and fortified cereals to support folate status.
• Vaccinations: Annual influenza, pneumococcal, and COVID‑19 vaccines are recommended, especially if immunosuppressed.

Psychosocial Support

Dealing with a potentially serious medication reaction can be stressful. Consider:

• Joining a patient support group (e.g., Arthritis Foundation).
• Speaking with a mental‑health professional if anxiety or depression develops.

Prevention

Most cases of toxicity are preventable with careful prescribing and monitoring.

Before Starting Methotrexate

• Baseline labs: CBC, LFTs, serum creatinine, hepatitis B/C, HIV (if risk factors), and pregnancy test for women of child‑bearing potential.
• Screen for drug interactions – ask about OTC meds, supplements, and herbal products.
• Counsel on the importance of daily folic acid (1 mg) supplementation.

During Therapy

• Adhere to dosing schedule (usually weekly, never daily).
• Schedule regular lab monitoring as described above.
• Educate patients on “red‑flag” symptoms that merit early contact.
• Adjust dose promptly if renal function declines (> 25 % rise in creatinine).

Special Situations

• Pregnancy: Methotrexate is teratogenic; avoid in women planning conception and discontinue at least 3 months before trying to become pregnant.
• Vaccinations: Live vaccines are contraindicated while on methotrexate.
• Procedures: Hold methotrexate 1 week before major surgery to reduce wound‑healing complications.

Complications if Untreated

Unchecked toxicity can progress to life‑threatening conditions.

• Bone‑marrow failure → severe infection, bleeding, anemia.
• Acute liver failure → coagulopathy, encephalopathy.
• Renal failure requiring dialysis.
• Pulmonary fibrosis – irreversible loss of lung function.
• Severe mucosal ulceration leading to infection and malnutrition.
• In rare cases, death (mortality rates up to 10 % in high‑dose MTX toxicity with delayed treatment) [NIH].

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, peer‑reviewed journals (e.g., *The Lancet Oncology*, *Arthritis & Rheumatology*). Information reviewed July 2024.

```